Peptides · Peptide comparison
Buserelin vs Leuprolide
A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility
A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.
- Hormone Support
- Hormone Support
At a glance
Quick comparison
Efficacy
Benefit ratings
Hormone Suppression
Cancer Management
Fertility Support
Endometriosis & Fibroid Relief
Hormone Control
Technical data
Compound specifications
Buserelin
- Molecular formula
- C60H86N16O13
- Molecular weight
- 1239.4 g/mol
- Half-life
- 2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
- Bioavailability
- ~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
- CAS number
- 57773-65-6
Leuprolide
- Molecular formula
- C59H84N16O12
- Molecular weight
- 1209.4 g/mol
- Half-life
- Approximately 2-6 hours (varies by route of administration)
- Bioavailability
- ~95% (subcutaneous injection)
- CAS number
- 74381-53-6
Protocols
Dosing compared
Buserelin
Subcutaneous
- 500 mcgEvery 8 hours (3 times daily) · First 7 daysThe product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
- 200 mcgOnce daily · Ongoing maintenanceAfter the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].
Intranasal
- 400 mcg (2 sprays per nostril)3 times daily (1,200 mcg/day) · Ongoing maintenanceThe nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].
Implant
- 6.3 mgOnce every 2 months · Long-termA long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
- 9.45 mgOnce every 3 months · Long-termA larger implant lasts about 3 months between placements [5].
Leuprolide
Subcutaneous
- 1 mgOnce daily · OngoingThe original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].
Intramuscular
- 7.5 mgEvery month · OngoingThe 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].
- 22.5 mgEvery 3 months · OngoingThe 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].
- 30-45 mgEvery 4-6 months · OngoingThe longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].
Applications
Best suited for
Buserelin
- Managing advanced prostate cancer
- Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Treating endometriosis and reducing associated pain
- Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Optimizing ovarian response during fertility treatments
- Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Leuprolide
- Managing advanced or metastatic prostate cancer
- Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][5].
- Controlling severe endometriosis pain
- Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
- Treating symptomatic uterine fibroids
- Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
- Delaying early puberty in children
- Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Safety profile
Side effects
Buserelin
No side effects recorded.
Leuprolide
Common
- Hot flashes (very common in men)
- Decreased libido and erectile dysfunction
- Injection site pain or swelling
- Nausea
- Fatigue
- Mood changes or depression
- Joint or muscle pain
- Headaches
- Dizziness
- Thinning hair
- Decreased bone density (osteoporosis with long-term use)
- QT prolongation (rare but serious cardiac effect)
- Tumor flare (temporary worsening of cancer symptoms in first weeks)
- Severe allergic reactions
- Spinal cord compression risk in men with metastatic disease
Serious
- Severe allergic reaction
Research status
Safety & evidence
Buserelin
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- Not FDA approved; no buserelin application in Drugs@FDA. Approved in Canada as SUPREFACT for advanced prostate cancer (injection and nasal solution) and endometriosis (nasal solution).
- Safety overview
- Buserelin is a GnRH agonist approved in Canada and Europe (not in the US), with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.
Contraindications
- Pregnancy or breastfeeding
- Hypersensitivity to GnRH agonists
- Certain bone diseases when long-term use is planned
Leuprolide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. [1] The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). [5] Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. [1][5] Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. [5]
Contraindications
- Pregnancy (may cause fetal harm) [6]
- Undiagnosed vaginal bleeding [6]
- Allergy to GnRH agonists or components [5][6]
Decision guide
Which is right for you?
Buserelin
Choose Buserelin if…
- Managing advanced prostate cancer
- Treating endometriosis and reducing associated pain
- Optimizing ovarian response during fertility treatments
Leuprolide
Choose Leuprolide if…
- Managing advanced or metastatic prostate cancer
- Controlling severe endometriosis pain
- Treating symptomatic uterine fibroids
- Delaying early puberty in children